Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01621490
Title PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications
Therapies
Age Groups: adult
Covered Countries USA | NLD | ESP

Facility Status City State Zip Country Details
Ucla Los Angeles California 90095 United States Details
University Of Chicago Chicago Illinois 60637 United States Details
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins Lutherville Maryland 21093 United States Details
Beth Israel Deaconess Medical Center (BIDMC) Boston Massachusetts 02215 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Massachusetts General Hospital Boston Massachusetts 02215 United States Details
Memorial Sloan-Kettering Cancer Center New York New York 10065 United States Details
Providence Portland Medical Center Portland Oregon 97213 United States Details
Vanderbilt-Ingram Cancer Ctr Nashville Tennessee 37232 United States Details
The University Of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
University Of Virginia Charlottesville Virginia 22908 United States Details
Seattle Cancer Care Alliance Seattle Washington 98109 United States Details
Local Institution Amsterdam 1066 CX Netherlands Details
Local Institution Pamplona 31192 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field